



## Clinical trial results:

### A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated

#### Summary

EudraCT number	2017-002499-14
Trial protocol	DE NL ES GB IE CZ GR PL FR Outside EU/EEA IT
Global end of trial date	02 July 2020

#### Results information

Result version number	v1 (current)
This version publication date	04 July 2021
First version publication date	04 July 2021

#### Trial information

##### Trial identification

Sponsor protocol code	CA017-055
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 October 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	02 July 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess safety and tolerability of the administered treatment

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	New Zealand: 1
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Japan: 1
Country: Number of subjects enrolled	United States: 2
Worldwide total number of subjects	20
EEA total number of subjects	11

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10
From 65 to 84 years	9
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

20 participants were randomized and treated.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Nivolumab + BMS-986205

Arm description:

Nivolumab 480 mg IV Q4W + BMS-986205 100 mg PO QD

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

480 mg IV Q4W

Investigational medicinal product name	BMS-986205
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg QD

<b>Arm title</b>	Nivolumab
------------------	-----------

Arm description:

Nivolumab 480 mg IV Q4W

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

480 mg IV Q4W

<b>Number of subjects in period 1</b>	Nivolumab + BMS-986205	Nivolumab
Started	10	10
Completed	2	1
Not completed	8	9
Participant request to discontinue treatment	-	1
Disease progression	4	6
Participant withdrew consent	1	-
Study drug toxicity	1	-
Other reasons	2	2

## Baseline characteristics

### Reporting groups

Reporting group title	Nivolumab + BMS-986205
-----------------------	------------------------

Reporting group description:

Nivolumab 480 mg IV Q4W + BMS-986205 100 mg PO QD

Reporting group title	Nivolumab
-----------------------	-----------

Reporting group description:

Nivolumab 480 mg IV Q4W

Reporting group values	Nivolumab + BMS-986205	Nivolumab	Total
Number of subjects	10	10	20
Age Categorical			
Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	4	6	10
>=65 years	6	4	10
Sex: Female, Male			
Units: Participants			
Female	4	4	8
Male	6	6	12
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	10	8	18
More than one race	0	0	0
Unknown or Not Reported	0	1	1
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	1
Not Hispanic or Latino	6	5	11
Unknown or Not Reported	4	4	8

## End points

### End points reporting groups

Reporting group title	Nivolumab + BMS-986205
Reporting group description: Nivolumab 480 mg IV Q4W + BMS-986205 100 mg PO QD	
Reporting group title	Nivolumab
Reporting group description: Nivolumab 480 mg IV Q4W	

### Primary: Number of Participants Experiencing Adverse Events

End point title	Number of Participants Experiencing Adverse Events <sup>[1]</sup>
End point description: Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation	
End point type	Primary
End point timeframe: From first dose to 100 days following last dose (up to approximately 27 months)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was performed for this endpoint.

End point values	Nivolumab + BMS-986205	Nivolumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	10		
Units: Participants				
Deaths	1	1		
Any cause AEs (any grade)	10	9		
Drug-related AEs (any grade)	9	7		
Any cause SAEs (any grade)	3	3		
Drug-related SAEs (any grade)	1	0		
SAEs leading to discontinuation	1	0		
Drug-Related Non-serious AEs leading to disc.	0	0		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events were collected from the first dose up to 30 days (inclusive) after the last dose of study treatment

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

### Reporting groups

Reporting group title	NIVOLUMAB + BMS-986205
-----------------------	------------------------

Reporting group description:

Subjects were orally administered with BMS-986205 100 milligrams (mg) once daily (QD) after a meal along with Nivolumab 480 mg as a 30-minute intravenous (IV) infusion every 4 weeks for up to 104 weeks.

Reporting group title	NIVOLUMAB
-----------------------	-----------

Reporting group description:

Subjects were administered Nivolumab 480 mg as a 30-minute IV infusion every 4 weeks for up to 104 weeks.

Serious adverse events	NIVOLUMAB + BMS-986205	NIVOLUMAB	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 10 (30.00%)	3 / 10 (30.00%)	
number of deaths (all causes)	1	3	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	



Renal and urinary disorders			
Renal failure			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Gastroenteritis viral			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	<b>NIVOLUMAB + BMS-986205</b>	<b>NIVOLUMAB</b>	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	9 / 10 (90.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	2	
Hypotension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	5 / 10 (50.00%)	2 / 10 (20.00%)	
occurrences (all)	6	2	
Chest discomfort			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	2 / 10 (20.00%)	2 / 10 (20.00%)	
occurrences (all)	2	2	
Influenza like illness			
subjects affected / exposed	2 / 10 (20.00%)	1 / 10 (10.00%)	
occurrences (all)	2	1	
Mucosal inflammation			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Pelvic pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Pruritus genital			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	2	

Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 10 (10.00%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Dyspnoea			
subjects affected / exposed	2 / 10 (20.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Dyspnoea exertional			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Hiccups			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Interstitial lung disease			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Obstructive airways disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Sleep apnoea syndrome			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Depressed mood			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 10 (10.00%) 1	
Investigations			
Amylase increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	0 / 10 (0.00%) 0	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 10 (0.00%) 0	
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 10 (10.00%) 1	
Lipase increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 5	0 / 10 (0.00%) 0	
Transaminases increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 10 (10.00%) 1	
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 10 (20.00%) 2	
Procedural pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 10 (0.00%) 0	
Radiation injury subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 10 (0.00%) 0	
Nervous system disorders			
Dysgeusia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 10 (10.00%) 1	
Headache subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 10 (20.00%) 2	
Lethargy			

subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Neuralgia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Paraesthesia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Presyncope			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Tremor			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Ocular discomfort			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Vitreous floaters			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Abdominal pain upper			

subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	2 / 10 (20.00%)	1 / 10 (10.00%)	
occurrences (all)	2	1	
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Dry mouth			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Dyspepsia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Nausea			
subjects affected / exposed	5 / 10 (50.00%)	3 / 10 (30.00%)	
occurrences (all)	5	5	
Proctalgia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Stomatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	1 / 10 (10.00%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Itching scar			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Rash macular			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Rash pruritic			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Sensitive skin			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Skin lesion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Solar dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Urinary incontinence			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Hypothyroidism			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Thyroiditis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 10 (20.00%)	3 / 10 (30.00%)	
occurrences (all)	2	4	

Bone pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Flank pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Myalgia			
subjects affected / exposed	0 / 10 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Pain in jaw			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Synovitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Trigger finger			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	3	0	
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Nasopharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Urinary tract infection			



subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	
occurrences (all)	2	1	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	3 / 10 (30.00%)	1 / 10 (10.00%)	
occurrences (all)	3	2	
Polydipsia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 10 (0.00%)	
occurrences (all)	2	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 June 2018	Enrollment of new subjects closed; treatment allocation unblinded; efficacy, PK, biomarker and PRO assessments will no longer be evaluated.
25 October 2018	Study unblinded

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported